Release Date: April 21, 2026
TAIPEI, TAIWAN – Elixiron Immunotherapeutics (7871.TWO, "Elixiron"), a clinical-stage biotechnology company, officially announced today that it has entered into a non-binding Memorandum of Understanding (MOU) regarding a potential financing arrangement with GEM Yield Bahamas Limited, an affiliate of the Global Emerging Markets Group ("GEM"). Under this strategic collaboration, Elixiron may have the option to access to a financing facility of up to NT$1.25 billion, which may support the advancement of its clinical development programs and general corporate growth.
International Capital Infusion as a Foundation for Clinical Development
The partner, GEM Group, is a Luxembourg-based investment institution managing a $3.4 billion asset portfolio, with offices in Paris, New York, and the Bahamas. GEM focuses on diversified investments in emerging markets and has successfully completed over 580 transactions across more than 70 countries. This alliance not only reflects international capital's recognition of Elixiron’s clinical development capabilities and future potential but may also provide additional financial flexibility.
Supporting the Pipeline: Clinical Development for Innovative Therapies
The potential proceeds, if drawn, from the financing facility of up to NT$1.25 billion are expected to be used primarily for Elixiron's research and clinical development. As drug R&D is highly capital-intensive and requires long-term commitment, these funds are expected to provide critical support in the following areas:
- Advancing Clinical Development Activities: Facilitating the progression of high potential drug candidates through clinical stages more efficiently.
- Expanding Early-Stage Discovery and Platforms: Enhancing R&D capacity to support the exploration of innovative early-stage therapies and further developing its immunotherapy platforms.
- Optimizing Global Intellectual Property and Regulatory Strategy: Supporting global patent filings and regulatory compliance across international markets.
"We are very much looking forward to our collaboration with GEM," stated the management team of Elixiron. "This agreement provides us with potential access to capital under certain terms, allowing our scientific team to focus on the development of innovative therapies . This is expected to enhance our competitive advantage in the global biopharmaceutical sector and represents an important step toward our goal of delivering new treatment options to patients with unmet medical needs."
Future Outlook and Risk Statement
This MOU is non-binding and remains subject to the execution of definitive agreements and customary conditions. Any potential funding under the arrangement will depend on the Company’s operational needs and satisfaction of applicable conditions. Elixiron will continue to advance its strategic plans steadily while seeking to strengthen its working capital through potential international funding sources.
Elixiron reminds investors that drug development is characterized by long timelines and high capital requirements, with no guarantee of success. Such uncertainties may pose investment risks. Investors are advised to exercise independent judgement and carefully evaluate these risks.
This news release contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ materially.
About the Companies
Elixiron Immunotherapeutics (7871.TWO): A biopharmaceutical company focused on the development of innovative therapies, Elixiron is committed to pioneering novel immunotherapies for autoimmune diseases, neurodegenerative disorders, and oncology. The company is currently listed on the Taipei Emerging Stock Board and continues to explore international funding opportunities to support its clinical development and research programs.
Global Emerging Markets Group (GEM): GEM is a $3.4 billion Luxembourg-based alternative investment group with offices in Paris, New York, and the Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets worldwide and has completed over 580 transactions in more than 70 countries.
【Contact Information】
Name：Mr. Chih-Hung Hsu
Position：Chief Financial Officer (CFO)
TEL：+886-2-27827700
Email：ir@elixiron.com
